Introduction
============

Gallbladder cancer(GBC) is a relatively rare primary malignancy, but it is the most common malignant neoplasm of the biliary tract, and one of the most aggressive cancers of the biliary tract with poor prognosis \[[@b1-crt-2019-370]\]. A variety of genetic and epigenetic alterations are associated with GBC, involving tumor suppressor genes, oncogenes, and DNA repair genes. Previous studies have focused on the importance of oncogenes (epidermal growth factor receptor \[EGFR\], K-Ras, and ERBB2), tumor suppressor genes (p53), cell cycle regulators (cyclin D1, cyclin E), and micro-RNAs in the development and prognosis of GBC. However, the precise information regarding genetic and molecular alterations in GBC is still poorly understood \[[@b2-crt-2019-370]\]. Li et al. \[[@b3-crt-2019-370]\] investigated genetic alterations in 57 GBC cases by whole exome and targeted sequencing, and found frequent mutations of *TP53*, *KRASK*, and *ERBB3*. Moreover, ErbB signaling, including EGFR, ERBB2, ERBB3, ERBB4, and their downstream genes is the most extensively mutated pathway, affecting 36.8% of patients with GBC. Although cytotoxic chemotherapy with the combination of gemcitabine and cisplatin has been accepted as the first-line therapy, the patient outcome is still disappointing. After ErbB signaling pathway was found to be one of the pathways contributing to gallbladder carcinoma, target-oriented agents, including monoclonal antibodies and tyrosine kinase inhibitors against EGFR and vascular endothelial growth factor have entered clinical trials \[[@b4-crt-2019-370],[@b5-crt-2019-370]\]. However, as those clinical trials revealed no, or marginal benefits, novels targets are needed to improve the patient outcomes.

The mesenchymal epithelial transition (MET) receptor tyrosine kinase pathway is one of the most commonly activated signaling pathways in primary human cancers. MET has a heterodimeric structure composed of an extracellular α subunit and a β chain that contains an extracellular domain, a transmembrane segment, and an intracellular tyrosine kinase region \[[@b6-crt-2019-370]\]. Activation of MET signaling has a critical role not only in tumor formation, progression, angiogenesis, and metastasis, but is also involved in mediating resistance against other targeted treatments \[[@b7-crt-2019-370],[@b8-crt-2019-370]\]. Hepatocyte growth factor (HGF), a ligand of MET, stimulates the tyrosine kinase activity of MET and activates multiple downstream signaling pathways, including the Grb2-Ras--mitogen-activated protein kinase (MAPK) cascade, the phosphatidylinositol-3 kinase (PI3K) pathway, the Wnt/β-catenin pathway, and the signal transducer and activator of transcription (STAT) pathway \[[@b9-crt-2019-370]\]. Dysregulation of MET protein has been reported in a variety of human malignancies and premalignant lesions, including hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC) \[[@b10-crt-2019-370],[@b11-crt-2019-370]\]. Accordingly, the possibility of targeting the *MET* gene in different cancer types is now being evaluated in clinical trials. Several drugs have been developed that target MET or HGF. These agents are divided into small molecule inhibitors and monoclonal antibodies. The small molecule tyrosine kinase inhibitors are further subdivided into multiple kinases and selective MET inhibitors. Crizotinib and cabozantinib are examples of multikinase MET inhibitors. Selective MET inhibitors include capmatinib and tepotinib. Monoclonal antibody therapy is divided into anti-MET antibodies, such as onartuzumab and emibetuzumab, and anti-HGF antibodies, including ficlatuzumab and rilotumumab \[[@b12-crt-2019-370]\].

As MET is a potential therapeutic target, information regarding its prevalence and clinicopathological relevance is important. However, the prevalence of MET overexpression and gene amplification in GBCs and its clinicopathological significance is not yet known precisely. Therefore, this study evaluated the expression level and gene copy number of MET in GBC tissues and their correlations with various clinicopathological characteristics, including patient's prognosis.

Materials and Methods
=====================

1. Patients and specimens
-------------------------

We examined 116 GBC samples (113 patients) obtained from consecutive surgical procedures performed at the Hanyang University Hospital between 1991 and 2016. Three patients had synchronous tumors in the gallbladder. The GBCs were assessed according to the system for staging primary tumor/regional lymph nodes/distant metastasis (TNM) described in the 8th American Joint Committee on Cancer (AJCC) cancer staging manual and histological classification according to the World Health Organization classification of tumors. The clinical data were retrospectively obtained from electronic medical records and included age at diagnosis, sex, pathological profiles (size, stage, histological grade, location, margin status, lymphovascular invasion, and perineural invasion), metastasis, recurrence, and date of death. Tumor recurrence was defined as tumor growth in any site of the body after the surgery, which was diagnosed clinically, radiologically, or pathologically, but mainly by computed tomography and ultrasonography. Among the 113 patients, 44 (37.9%) were men, and the median age was 63.5 years (range, 28 to 90 years). The tumor types of gallbladder were as follows: adenocarcinoma (n=109), squamous carcinoma (n=2), adenosquamous carcinoma (n=4), and small cell carcinoma (n=1). The detailed clinicopathological features are described in [Table 1](#t1-crt-2019-370){ref-type="table"}.

2. Tissue microarray construction
---------------------------------

Hematoxylin and eosin slides made from formalin-fixed paraffin-embedded tissue blocks were reviewed, and the most representative tumor regions without necrosis and hemorrhage were carefully selected and marked. Single tissue cores, each 3.0 mm in diameter, were punched from each paraffin block and assembled into a new recipient paraffin block using a manual tissue microarray (TMA) instrument (Quick-Ray, Unitma, Seoul, Korea). A total of four TMA blocks were constructed.

3. Immunohistochemistry
-----------------------

Immunohistochemical staining (IHC) was performed on Ventana BenchMark XT autostainer (Ventana Medical Systems, Tucson, AZ), according to the manufacturer's protocol. The primary antibody used was anti-MET (clone sp44) rabbit monoclonal antibody (Ventana Medical Systems).

Two pathologists (K.J. and Y.K.) independently evaluated MET IHC. The immunoreactivity was scored using a fourtier system, which has been established in previous studies on MET IHC scoring system in NSCLC \[[@b13-crt-2019-370]\]. This system was used to evaluate both proportion and staining intensity: 0, no staining or \< 50% tumor cells with any intensity; 1+, ≥ 50% of tumor cells staining with weak or higher staining but \< 50% with moderate or higher strong intensity; 2+, ≥ 50% of tumor cells with moderate or higher staining but \< 50% with strong intensity; 3+, ≥ 50% of tumor cells staining with strong intensity. Samples exhibiting 2+ or 3+ immunostaining were considered positive for MET overexpression.

4. *In situ* hybridization
--------------------------

MET silver *in situ* hybridization (SISH) was performed on an automated Ventana BenchMark XT platform (Ventana Medical Systems), according to the manufacturer's protocols and using both MET-specific and centromere 7 (CEP7)-specific probes. Fluorescence *in situ* hybridization (FISH) was used to confirm *MET*-amplified cases by SISH. FISH was performed using Zytolight SPEC MET/CEN7 Dual color probe (Zytovision, Bremerhaven, Germany), according to the manufacturer's protocol.

The gene copy number was assessed independently by two pathologists (K.J. and Y.K.) and the number of MET and CEP7 signals was counted in at least 40 tumor cell nuclei in "hot spot" area (80 nuclei if there was no agreement). Then, the mean number of MET and CEP7 copies per nuclei and the MET/CEP7 ratio was calculated. We used the four different scoring systems for *in situ* hybridization (ISH) interpretation.

\- Method A: High-level amplification was defined in tumors with a MET/CEP7 ratio ≥ 2.0, an average MET gene copy number per cell of ≥ 6.0, or ≥ 10% of tumor cells containing ≥ 15 MET signals. Intermediate level of gene copy number gain being defined as ≥ 50% of cells containing ≥ 5 MET signals and criteria for high-level amplification are not fulfilled. Low level of gene copy number gain was defined as ≥ 40% of tumor cells showing ≥ 4 MET signals and criteria for high-level amplification or intermediate level of gene copy number gain are not fulfilled. All other tumors were classified as negative \[[@b14-crt-2019-370]\].

\- Method B: Tumors with a mean gene copy number of ≥ 5 MET signals per tumor cell were classified as *MET* amplification \[[@b15-crt-2019-370]\].

\- Method C: Tumors with a MET/CEP7 ratio ≥ 2 were defined as MET amplification by PathVysion \[[@b16-crt-2019-370],[@b17-crt-2019-370]\].

\- Method D: High-level amplification (presence of loose or tight clusters of MET signals too numerous to count) was defined in tumors with MET/CEP7 ratio more than 5.0. Low-level amplification was defined in tumors with MET/CEP7 ratio ≥ 2.2 and ≤ 5.0 \[[@b18-crt-2019-370]\].

5. Targeted sequencing by Oncomine comprehensive assay
------------------------------------------------------

DNA and total RNA were extracted by using RecoverAll Multi-Sample RNA/DNA Isolation Workflow (Invitrogen, Waltham, MA) according to the manufacturer\'s instructions. Library preparation for each sample was performed using the multiplex PCR-based Ion Torrent AmpliSeq technology (Thermo Fisher Scientific, Waltham, MA), together with the Oncomine comprehensive assay (OCA) v1 panel (Thermo Fisher Scientific) according to the manufacturer\'s protocol. OCA v1 panel covers multiple exons in 143 genes with 156 amplicons. Next generation sequencing (NGS) was performed on the Ion Torrent S5XL using an Ion 540 chip (PGM, Life Technologies, Grand Island, NE). Results were analyzed using the Variant caller by aligning the reads to the hg19 reference genome, calling the variants, and generating an interactive report for visualization and quality control. Data analysis was performed using Ion Reporter Server hosting informatic tools (Ion Reporter Software v5.0) for variant analysis, filtering, and annotations.

6. Statistical analysis
-----------------------

To analyze the association between the clinicopathological features and *MET* gene copy number status as well as MET protein expression, chi-square test was employed. Diseasefree survival and overall survival (OS) were determined using Kaplan-Meier survival curves, and the log-rank test was used to compare the differences. The Cox proportional hazard regression model was used to evaluate the independent prognostic significance. All statistical analyses were carried out using SPSS for Windows ver. 19.0 software (SPSS Inc., Chicago, IL), and p \< 0.05 was considered as statistically significant.

7. Ethical statement
--------------------

This study was approved by the Institutional Review Board of Hanyang University Hospital (IRB No. 2018-08-031-002). Waiver of informed consent for this study was obtained from IRB based on the retrospective analyses of archived tissues and clinical data.

Results
=======

1. MET overexpression and gene amplification in GBCs
----------------------------------------------------

MET IHC was successfully performed in 93/116 tissue cores (80.2%). The unsuccessful staining was mainly due to empty TMA cores or absence of tumor cells. Many tissue cores showed focal or diffuse cytoplasmic/membranous staining pattern with varying intensity. MET IHC score 0-3 was observed in 26 (28.0%), 30 (32.3%), 22 (23.7%), and 15 (16.1%) tumors, respectively. MET overexpression, defined by IHC score 2 or more, was found in 37/93 (39.8%) GBC tumor tissues ([Fig. 1](#f1-crt-2019-370){ref-type="fig"}).

SISH was successful in 93/116 tissue cores (80.2%), and 17/93 (18.3%), 9 (9.7%), 12 (12.9%), and 11 (13.4%) showed *MET* gene amplification according to four different interpretation methods ([Table 2](#t2-crt-2019-370){ref-type="table"}). FISH was performed in same TMA sections and all cases showed concordant results with SISH. The representative images of SISH and FISH are shown in [Fig. 2](#f2-crt-2019-370){ref-type="fig"}.

To identify the intratumoral heterogeneity of *MET* copy number, we performed ISH on whole tissue sections in subset of amplified cases (6 out of 17 cases). Because the assessment of heterogeneity is difficult on FISH slide due to dark field, we performed bright field SISH to observe morphologic detail. As we expected, intratumor heterogeneity of MET copy number was found within the tumors ([Fig. 3](#f3-crt-2019-370){ref-type="fig"}).

Tumors with high-level *MET* amplification tended to express higher MET protein expression than those with low-level copy number gain or no copy number gain ([S1 Table](#SD1-crt-2019-370){ref-type="supplementary-material"}). *MET* gene copy number was marginally higher for MET overexpressed tumors. (mean *MET* gene copy number, 2.2 vs. 1.9). However, no statistically significant correlation was found between MET protein overexpression and gene copy number changes.

Targeted sequencing data was available in 17 cases. *MET* copy number ranged from 0 to 9.9 (mean, 2.53). No *MET*-amplified case was detected by NGS method in all 17 cases ([S2 Table](#SD2-crt-2019-370){ref-type="supplementary-material"}).

2. Correlation between MET overexpression/amplification and clinicopathological characteristics in GBCs
-------------------------------------------------------------------------------------------------------

MET protein expression by immunohistochemistry, including the proportion of positive tumor cells, the staining intensity, and IHC scores, were not correlated with any clinicopathological characteristics ([S3 Table](#SD3-crt-2019-370){ref-type="supplementary-material"}).

*MET* amplification by the criteria of Schildhaus et al. \[[@b14-crt-2019-370]\] (method A) significantly correlated with higher histological grade (p=0.038), advanced T category (p=0.001), frequent lymph node metastasis (p=0.011), and advanced AJCC stage (p \< 0.001). *MET*-amplified tumors by the criteria of Cappuzzo et al. \[[@b15-crt-2019-370]\] (method B) showed higher histological grade (p=0.011), advanced T category (p=0.007), frequent lymph node metastasis (p=0.003), and advanced AJCC stage (p=0.013). MET amplification by the criteria of PathVysion \[[@b16-crt-2019-370],[@b17-crt-2019-370]\] (method C) correlated with higher histological grade (p=0.011), advanced T category (p=0.003), frequent lymph node metastasis (p=0.003), presence of perineural invasion (p=0.026), and advanced AJCC stage (p=0.001). MET amplification by the criteria of Ou et al. \[[@b18-crt-2019-370]\] (method D) correlated with higher histological grade (p=0.006), advanced T category (p=0.007), frequent lymph node metastasis (p=0.006), presence of perineural invasion (p=0.015), and advanced AJCC stage (p=0.003) ([Table 3](#t3-crt-2019-370){ref-type="table"}).

3. Survival analysis of MET expression and gene amplification in GBCs
---------------------------------------------------------------------

The median recurrence-free survival (RFS) and OS for all patients were 38.6 months and 64.7 months, respectively. Survival analyses were performed to evaluate the conventional pathological prognostic factors of our cohort. Histological grade (p=0.088 and p=0.001), advanced T stage (both p \< 0.001), lymph node metastasis (p=0.001 and p \< 0.001), distant metastasis (both p \< 0.001), advanced AJCC stage (both p \< 0.001), lymphovascular invasion (both p \< 0.001), and perineural invasion (both p \< 0.001) were revealed as predictors of poor RFS and OS, respectively ([Table 4](#t4-crt-2019-370){ref-type="table"}).

Neither MET protein expression nor *MET* amplification status showed a significant association with patient's survival ([Table 4](#t4-crt-2019-370){ref-type="table"}, [Fig. 4](#f4-crt-2019-370){ref-type="fig"}). However, patients with *MET*-amplified tumor, defined by criteria of Schildhaus et al. \[[@b14-crt-2019-370]\] (method A), exhibited shorter OS compared to those with the nonamplified tumor (median OS, 26.8 months vs. 72.3 months). The median RFS of the patients with MET-amplified tumor was also shorter than those with the non-amplified tumor (median RFS, 16.0 months vs. 51.7 months). Similar results were observed with other criteria for *MET* amplification.

Discussion
==========

MET is a transmembrane protein, which acts as a receptor of HGF. The binding of HGF to the MET protein triggers several downstream signaling pathways, including PI3K/AKT, MAPK, Wnt/β-catenin, and STAT signaling pathways \[[@b19-crt-2019-370]\]. Activation of these pathways can drive various biological processes related to cancer, such as cell proliferation, migration, invasion, inhibition of apoptosis, epithelial to mesenchymal transition, and angiogenesis \[[@b8-crt-2019-370],[@b19-crt-2019-370]\]. MET was first identified in a human osteosarcoma as an oncogene, in the form of TPR-MET fusion \[[@b20-crt-2019-370]\]. Then, dysregulation of MET protein and amplification had been found in several human malignancies including gastric \[[@b21-crt-2019-370]\], colorectal \[[@b22-crt-2019-370]\], breast \[[@b23-crt-2019-370]\], and NSCLC \[[@b10-crt-2019-370]\].

The oncogenic role of MET was also investigated in biliary tumors, including intra- and extrahepatic cholangiocarcinomas and GBCs. MET overexpression has been observed in the neoplastic glandular epithelium of furan-induced rat cholangiocarcinomas \[[@b24-crt-2019-370]\]. Previous studies with clinical samples have investigated MET expression by IHC and demonstrated that the prevalence of MET overexpression in GBCs was variable and ranged from 5% to 74% ([Table 5](#t5-crt-2019-370){ref-type="table"}) \[[@b25-crt-2019-370]-[@b29-crt-2019-370]\]. This variability might be due to the difference in primary antibodies used in IHC and interpretation criteria for overexpression. Moon et al. \[[@b28-crt-2019-370]\] revealed that MET overexpression was observed in 74% of the GBC cases and associated with invasion depth and increased staining intensity of MET at the invasive front of GBCs, which suggested their important role in tumor invasion \[[@b28-crt-2019-370]\]. However, Sanada et al. \[[@b27-crt-2019-370]\] found diffuse membranous staining of MET in the intraductal neoplastic components and no staining in the invasive components, suggesting that MET overexpression might be related to early events of carcinogenesis rather than tumor progression \[[@b27-crt-2019-370]\]. Yang et al. \[[@b26-crt-2019-370]\] found that MET overexpression correlated with adverse clinicopathological factors, such as lymph node metastasis, invasion, and decreased OS. In our study, MET overexpression was observed in 39.8% of GBCs. The interpretation criteria of overexpression used in this study was adopted from a previous clinical trial, which revealed that dual MET/EGFR inhibition was clinically beneficial in NSCLC only in the MET overexpression group. However, no significant correlation was observed between MET overexpression and clinicopathological features in our GBC cohort. We performed IHC and SISH on whole tissue sections in subset of cases. Although the different MET immunoreactivity and gene copy number is observed at different areas within tumor, there is no tendency of increased MET immunoreactivity or gene copy number at invasive front as compared to tumor center. Although some previous studies have found no clinicopathological significance of MET overexpression \[[@b25-crt-2019-370],[@b29-crt-2019-370]\], other studies have shown significant correlation with worse prognostic factors \[[@b26-crt-2019-370],[@b28-crt-2019-370]\]. These discrepancies might be due to different ethnicities of cohorts, the definition of overexpression used, and relatively small number of tumor samples.

Only one ISH study on the *MET* gene copy number in GBCs was found in the literature, and it revealed that no amplification was detected in 89 cases of GBCs \[[@b25-crt-2019-370]\]. The previous studies using NGS data reported that *MET* amplification was rare event in GBCs \[[@b30-crt-2019-370],[@b31-crt-2019-370]\]. In our study, no *MET* amplification was detected by NGS method in 17 available cases. However, we found that 18.3% of GBCs showed *MET* amplification by ISH. This discrepancy between ISH and NGS methods for *MET* copy number evaluation may be resulted from intratumoral heterogeneity, contamination of non-neoplastic stromal and immune cells, and different threshold for detecting copy number alteration in high throughput data. However, the most important strength of tissue section based ISH method is that we can discriminate tumor cells from other non-neoplastic components. The tumor cellularity of GBC used in sequencing is generally low and usually less than 50%. In the previous study, there have been reported intratumoral heterogeneity of MET expression in solid tumors \[[@b32-crt-2019-370],[@b33-crt-2019-370]\]. We also identified intratumoral heterogeneity of MET expression and amplification on whole tissue sections.

*MET* amplification, regardless of interpretation criteria, showed significant association with the adverse clinicopathological features, including higher histological grade, advanced pT category, frequent lymph node metastasis, and advanced AJCC stage. Moreover, *MET* amplification showed a tendency to shorten OS and RFS, which were not statistically significant.

We investigated the correlation between MET protein expression and gene amplification. However, there was no correlation between MET protein overexpression and amplification, although the incidence of MET overexpression tended to be higher in tumors from patients with *MET* amplification than that in tumors from patients with no amplification. Some studies have shown lack of correlation between MET overexpression and gene amplification in HCC and NSCLC \[[@b34-crt-2019-370],[@b35-crt-2019-370]\]. These studies and our results suggested that other than gene amplification, there are different mechanisms of protein overexpression. It can be inferred that the other mechanisms, including autocrine and paracrine HGF, increased expression of HGF activator, ligand-independent interactions with other receptors, interactions with other active cell-surface receptors and/or epigenetic regulation might play an important role in MET expression without genomic amplification \[[@b19-crt-2019-370],[@b36-crt-2019-370],[@b37-crt-2019-370]\]. Additionally, activation of other oncogenic factors, inactivation of tumor suppressors, such as TP53, and upregulated microRNAs have been known to enhance MET transcription \[[@b38-crt-2019-370]\].

In conclusion, the present study found that *MET* amplification was observed in approximately 20% of the GBCs, and that it was associated with adverse clinicopathological characteristics, such as histological grade, T category, lymph node metastasis, and AJCC stage. Further studies are needed to elucidate the significance of *MET* amplification as a potential therapeutic target and predictive biomarker for antiMET-targeted therapy in GBC patients.
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Association of M ET protein expression with SISH analysis

###### 

Results of NGS in gallbladder cancer

###### 

Correlations between MET over expression and various clinicopatholog ical parameters in gall bladder cancer

![Representative sections of immunohistochemical (IHC) scores for MET expression in gallbladder cancers (×400). (A) IHC score 3, strong cytoplasmic/membranous staining in almost all tumor cells. (B) IHC score 2, more than 50% of tumor cells with moderate staining intensity but \< 50% strong intensity. (C) IHC score 1, weak staining in more than 50% of tumor cells. (D) IHC score 0, no staining observed in invasive tumor cells.](crt-2019-370f1){#f1-crt-2019-370}

![Representative sections of silver *in situ* hybridization (SISH) and fluorescence *in situ* hybridization (FISH) analyses of MET/centromere 7 (CEP7) (×1,000). (A) SISH, no MET amplification, 1-2 MET gene signals (black), and 1-2 CEP7 signals (red) were present in each nucleus. (B) SISH, low-grade MET copy number gain, 2-7 MET gene signals (black), and 1-2 CEP7 (red) were present in each nucleus. (C) SISH, high-level amplification, 7-8 or more MET gene signals (black), and 1-5 CEP7 (red) were present in each nucleus. (D) FISH, high-level amplification, 5-10 or more MET gene signals (green), and 4-5 CEP7 (red) were present in each nucleus.](crt-2019-370f2){#f2-crt-2019-370}

![Representative section of silver *in situ* hybridization on whole section. (A) Yellow and red circle highlight the nonamplified lesion and amplified lesion, respectively. (B) The tumor cells exhibit 1-2 c-*MET* gene signals (black), and 1-2 centromere 7 signals (red) in each nucleus. (C) In the amplified lesion, tumor cells exhibit 4-12 c-*MET* gene signals (×1,000).](crt-2019-370f3){#f3-crt-2019-370}

![Kaplan-Meier survival curves of gallbladder cancer patients stratified on the basis of *MET* amplification status. (A) Recurrence-free survival (RFS) according to *MET* amplification (log-rank test, p=0.436). (B) Overall survival (OS) according to *MET* amplification (log-rank test, p=0.121).](crt-2019-370f4){#f4-crt-2019-370}

###### 

Histological and clinical characteristics of gallbladder cancer patients

  Clinicopathological characteristic   No. (%)
  ------------------------------------ ------------
  **Age (yr)**                         
   \< 65                               60 (53.1)
   ≥ 65                                53 (46.9)
  **Sex**                              
   Male                                44 (38.9)
   Female                              69 (61.1)
  **Histological type**                
   Adenocarcinoma                      109 (94.0)
   Squamous                            2 (1.7)
   Adenosquamous                       4 (3.4)
   Small cell neuroendocrine           1 (0.9)
  **Histological grade**               
   *In situ*                           6 (5.5)
   Well                                26 (23.9)
   Moderate                            50 (45.9)
   Poor                                27 (24.8)
  **T category**                       
   Tis                                 6 (5.3)
   T1a                                 8 (7.1)
   T1b                                 8 (7.1)
   T2                                  46 (40.7)
   T3                                  37 (32.7)
   T4                                  8 (7.1)
  **AJCC stage**                       
   0                                   6 (5.3)
   Ⅰ                                   16 (14.2)
   Ⅱ                                   31 (27.4)
   Ⅲ                                   44 (38.9)
   Ⅳ                                   16 (14.2)
  **Lymph node metastasis**            
   N0                                  56 (57.1)
   N1                                  31 (31.6)
   N2                                  11 (11.2)
  **Distant metastasis**               
   M0                                  103 (91.2)
   M1                                  10 (8.8)
  **Lympho-vascular invasion**         
   Absent                              58 (64.3)
   Present                             55 (35.7)
  **Perineural invasion**              
   Absent                              72 (63.7)
   Present                             41 (36.3)

AJCC, American Joint Committee on Cancer.

###### 

Prevalence of *MET* amplification in gallbladder cancers according to different interpretation criteria

             Reference                                                Classification   No.   No. of amplified cases (%)
  ---------- -------------------------------------------------------- ---------------- ----- ----------------------------
  Method A   Schildhaus et al. \[[@b14-crt-2019-370]\]                High             12    17 (18.3)
                                                                      Intermediate     0     
                                                                      Low              5     
                                                                      Negative         76    
  Method B   Cappuzzo et al. \[[@b15-crt-2019-370]\]                  Positive         9     9 (9.7)
                                                                      Negative         84    
  Method C   PathVision \[[@b16-crt-2019-370],[@b17-crt-2019-370]\]   Positive         12    12 (12.9)
                                                                      Negative         81    
  Method D   Ou et al. \[[@b18-crt-2019-370]\]                        High             0     11 (13.4)
                                                                      Low              11    
                                                                      Negative         82    

###### 

Correlations between *MET* amplification and various clinicopathological parameters of gallbladder cancer patients

  Characteristic                No.   Method A    Method B    Method C   Method D                                                                                   
  ----------------------------- ----- ----------- ----------- ---------- ----------- ---------- --------- ----------- ----------- --------- ----------- ----------- -------
  **Age (yr)**                                                                                                                                                      
   \< 65                        47    40 (85.1)   7 (14.9)    0.432      42 (89.4)   5 (10.6)   \> 0.99   41 (87.2)   6 (12.8)    \> 0.99   42 (89.4)   5 (10.6)    0.759
   ≥ 65                         46    36 (78.3)   10 (21.7)              42 (91.3)   4 (8.7)              40 (87.0)   6 (13.0)              40 (87.0)   6 (13.0)    
  **Sex**                                                                                                                                                           
   Male                         36    30 (83.3)   6 (16.7)    0.791      31 (86.1)   5 (13.9)   0.301     31 (86.1)   5 (13.9)    \> 0.99   31 (86.1)   5 (13.9)    0.745
   Female                       57    46 (80.7)   11 (19.3)              53 (93.0)   4 (7.0)              50 (87.7)   7 (12.3)              51 (89.5)   6 (10.5)    
  **Histological grade**                                                                                                                                            
   G1, G2                       69    60 (87.0)   9 (13.0)    0.038      66 (95.7)   3 (4.3)    0.011     64 (92.8)   5 (7.2)     0.011     65 (94.2)   4 (5.8)     0.006
   G3                           19    12 (63.2)   7 (36.8)               14 (73.7)   5 (26.3)             13 (68.4)   6 (31.6)              13 (68.4)   6 (31.6)    
  **T category**                                                                                                                                                    
   Tis, T1, T2                  61    56 (91.8)   5 (8.2)     0.001      59 (96.7)   2 (3.3)    0.007     58 (95.1)   3 (4.9)     0.003     58 (95.1)   3 (4.9)     0.007
   T3, T4                       32    20 (62.5)   12 (37.5)              25 (78.1)   7 (21.9)             23 (71.9)   9 (28.1)              24 (75.0)   8 (25.0)    
  **N category**                                                                                                                                                    
   N0                           46    41 (89.1)   5 (10.9)    0.011      45 (97.8)   1 (2.2)    0.003     44 (95.7)   2 (4.3)     0.003     44 (95.7)   2 (4.3)     0.006
   N1, N2                       33    21 (63.6)   12 (36.4)              25 (75.8)   8 (24.2)             23 (69.7)   10 (30.3)             24 (72.7)   9 (27.3)    
  **M category**                                                                                                                                                    
   M0                           86    69 (80.2)   17 (19.8)   0.342      77 (89.5)   9 (10.5)   \> 0.99   74 (86.0)   12 (14.0)   0.367     75 (87.2)   11 (12.8)   0.593
   M1                           7     7 (100)     0                      7 (100)     0                    7 (100)     0                     7 (100)     0           
  **AJCC stage**                                                                                                                                                    
   I, II                        48    46 (95.8)   2 (4.2)     \< 0.001   47 (97.9)   1 (2.1)    0.013     47 (97.9)   1 (2.1)     0.001     47 (97.9)   1 (2.1)     0.003
   III, IV                      45    30 (66.7)   15 (33.3)              37 (82.2)   8 (17.8)             34 (75.6)   11 (24.4)             35 (77.8)   10 (22.2)   
  **Lymphovascular invasion**                                                                                                                                       
   Absent                       49    43 (87.8)   6 (12.2)    0.181      46 (93.9)   3 (6.1)    0.466     45 (91.8)   4 (8.2)     0.336     46 (93.9)   3 (6.1)     0.180
   Present                      43    33 (76.7)   10 (23.3)              38 (88.4)   5 (11.6)             36 (83.7)   7 (16.3)              36 (83.7)   7 (16.3)    
  **Perineural invasion**                                                                                                                                           
   Absent                       58    50 (86.2)   8 (13.8)    0.161      55 (94.8)   3 (5.2)    0.067     54 (93.1)   4 (6.9)     0.026     55 (94.8)   3 (5.2)     0.015
   Present                      33    24 (72.7)   9 (27.3)               27 (81.8)   6 (18.2)             25 (75.8)   8 (24.2)              25 (75.8)   8 (24.2)    

Values are presented as number (%). AJCC, American Joint Committee on Cancer.

###### 

Univariate Cox regression analysis of variables related to the prognosis of gallbladder cancer

  Variable                                                                                Recurrence-free survival   Overall survival                                     
  --------------------------------------------------------------------------------------- -------------------------- ------------------ ---------- ------- -------------- ----------
  Age (\< 65 yr vs. ≥ 65 yr)                                                              1.075                      0.687-1.682        0.750      1.388   0.870-2.214    0.169
  Sex (male vs. female)                                                                   1.324                      0.830-2.112        0.239      1.206   0.745-1.953    0.447
  Histologic grade (G1, G2 vs. G3)                                                        1.698                      0.923-3.122        0.088      0.813   1.263-2.604    0.001
  T category (Tis, T1, T2 vs. T3, T4)                                                     2.464                      1.565-3.880        \< 0.001   2.539   1.575-4.093    \< 0.001
  Lymph node metastasis (N0 vs. N1, N2)                                                   2.462                      1.470-4.124        0.001      2.749   1.584-4.769    \< 0.001
  Distant metastasis (M0 vs. M1)                                                          5.639                      2.733-11.639       \< 0.001   6.157   2.984-12.703   \< 0.001
  AJCC stage (I, II vs. III, IV)                                                          2.705                      1.681-4.353        \< 0.001   2.870   1.731-4.759    \< 0.001
  Lymphovascular invasion (absent vs. present)                                            2.457                      1.545-3.909        \< 0.001   2.753   1.698-4.464    \< 0.001
  Perineural invasion (absent vs. present)                                                3.045                      1.856-4.994        \< 0.001   3.643   2.185-6.071    \< 0.001
  MET amplification (absent vs. present)^[a)](#tfn1-crt-2019-370){ref-type="table-fn"}^   1.299                      0.668-2.525        0.299      1.667   0.868-3.202    0.125
  MET overexpression (score 0-1 vs. score 2-3)                                            0.935                      0.587-1.490        0.777      1.040   0.641-1.688    0.873

AJCC, American Joint Committee on Cancer.

By the criteria of Schildhaus et al. \[[@b14-crt-2019-370]\] (method A).

###### 

Prevalence of MET overexpression and amplification in previous studies

  Study                                     No. of patients                        Detection   Cut-off for MET overexpression                                       Prevalence of MET overexpression (%)           Clinicopathological correlation
  ----------------------------------------- -------------------------------------- ----------- -------------------------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------
  Moon et al. \[[@b28-crt-2019-370]\]       28 Invasive GBC                        IHC         Staining intensity with 1+, 2+ or 3+, more than 10% of tumor cells   74 of GBCs, especially in the invasive front   Associated with depth of invasion
  8 *In situ* carcinoma                                                                                                                                                                                            
  7 Adenoma                                                                                                                                                                                                        
  Nakazawa et al. \[[@b25-crt-2019-370]\]   89 GBC                                 IHC         Staining intensity with 2+ or 3+                                     5.6                                            No correlation
  FISH                                      No *MET* amplification detected                                                                                                                                        
  Sanada et al. \[[@b27-crt-2019-370]\]     14 Biliary cancers, including 5 GBCs   IHC         Diffuse membranous or cytoplasmic staining in greater than 30%       28.6 of biliary cancers                        N/A
  Yang et al. \[[@b26-crt-2019-370]\]       108 GBCs                               IHC         Percentage of positive tumor cells with 25% or more                  55.6                                           Associated with differentiation, lymph node metastasis, depth of invasion, poor overall survival
  Heo et al. \[[@b29-crt-2019-370]\]        12 GBC                                 IHC         Staining intensity with 2+ or 3+, more than 10% of tumor cells       41.7                                           No correlation

GBC, gallbladder cancer; IHC, immunohistochemistry; FISH, fluorescence *in situ* hybridization; N/A, not available.
